Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
113.27
+4.78 (4.41%)
Aug 12, 2026, 3:50 PM EDT - Market open
Dianthus Therapeutics Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, Dianthus Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $137.62. The average 1-year stock price forecast is 21.50% higher than the current stock price, while the lowest is $109 (-3.77%) and the highest is $200 (+76.57%).
Price Target: $137.62 (+21.50%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Dianthus Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 15 | 16 | 15 | 15 | 15 | 14 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 16 | 15 | 15 | 15 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI | Evercore ISI | Buy Maintains $134 | Buy | Maintains | $134 | +18.30% | Aug 10, 2026 |
| Truist Financial | Truist Financial | Buy Maintains $110 → $128 | Buy | Maintains | $110 → $128 | +13.00% | Aug 6, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $200 | Buy | Reiterates | $200 | +76.57% | Aug 6, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $130 → $158 | Buy | Reiterates | $130 → $158 | +39.49% | Aug 6, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $133 | Buy | Maintains | $133 | +17.42% | Aug 6, 2026 |
Financial Forecast
Revenue This Year
1.81M
from 2.04M
Decreased by -10.92%
Revenue Next Year
2.06M
from 1.81M
Increased by 13.55%
EPS This Year
-3.92
from -4.20
EPS Next Year
-4.74
from -3.92
EPS and Forward PE are based on non-GAAP adjusted numbers.